AfriAg Global Plc - Apollon's Dr Barnhill - Keynote Speaker Cannabiz
PR Newswire
London, May 28
28 May 2019
AfriAg Global PLC
('AfriAg' or the 'Company')
Apollon's Dr Stephen Barnhill - Keynote Speaker at Jamaica Cannabiz Conference
AfriAg Global PLC, a company whose shares are admitted to trading on London's NEX Exchange, is pleased to announce that Dr Stephen Barnhill was a keynote speaker on the weekend at the Second Jamiaca Cannabiz Conference at the Faculty of Law, University of the West Indies, in Kingston Jamaica.
Dr Barnill is the key person behind Apollon Formularies Ltd ("Apollon"), in which the Company announced a significant investment multi-staged transaction on 16 May 2019.
About Dr. Stephen Barnhill (Proposed Chairman and Managing Director of the Company, subject to the Right of First Refusal being exercised as announced on 16 May 2019)
Dr. Stephen D. Barnhill is a physician, Fellowship trained in Laboratory Medicine and Board Certified by the American Board of Bioanalysis. Dr. Barnhill is currently Chairman and CEO of Doc's Place International, Inc., the first Global Centre of Excellence for Medical Cannabis Therapy in Negril, Jamaica, as well as, Chairman and CEO Apollon Formularies, Inc., a U.S. affiliate of Apollon Formularies Jamaica, Limited to which he also serves as President and Board Member.
Dr. Barnhill has been a founder, Chairman and CEO of both private and public companies. He was most recently founder, Chairman and CEO of a U.S. publicly traded international biotech company, which he took from inception to profitability. In addition, he was founder, Chairman and CEO of BCL laboratories, LLC with operations in south-eastern U.S. which was acquired by Corning-MetPath, now Quest Diagnostics, the largest clinical laboratory in the world. Dr. Barnhill served as a Medical Director for Quest Diagnostics for approximately 5 years after the acquisition. Dr. Barnhill was also founder, Chairman and CEO of National Medical Specialty Labs, which was acquired by Horus Therapeutics Inc., a New York based pharmaceutical company. Dr. Barnhill served as President of Horus Therapeutics for several years after the acquisition. Dr. Barnhill is a pioneer in artificial intelligence machine learning (pattern recognition algorithms) and an inventor on more than 40 patents including neural networks and support vector machines ("SVM") including the Hallmark SVM-RFE technique now cited by more than 10,000 publications. His patents were part of the intellectual property portfolio that won 1st Place out of 1600 publicly traded companies and was awarded the MICO award from MDB Capital for the most disruptive intellectual property portfolio. Dr. Barnhill's neural network patents were acquired by Johnson & Johnson. He is also an inventor on patents related to laboratory developed tests and tumour markers. His work includes expertise in the clinical laboratory involving clinical chemistry, haematology, microbiology, blood banking, toxicology and immunology, as well as diagnostic test development relating to cancers of the prostate, pancreas, breast and ovary, cytogenetics, flow cytometry, FISH and imaging in digital mammography, and funduscopic analysis of macular degeneration (AMD). He was part of the team that launched the first iPhone app using SVM for melanoma detection. Dr. Barnhill has negotiated and executed deals with many companies, including Pfizer, Corning-Metpath, Quest Diagnostics, Clarient (now GE Healthcare), LabCorp, NeoGenomics, Abbot, Bruker and others. He has published many peer reviewed papers with academics including those from MD Anderson Cancer Centre, Johns Hopkins University Medical Centre, Stanford University Medical Centre and others. He is a frequently invited speaker to medical conferences in the US and internationally. He has raised millions of dollars in start-up and ongoing financing for both private and public companies.
Dr. Barnhill is or has been a Member or Fellow of the American College of Physician Inventors, the American College of International Physicians, the American Medical Association, the American College of Physician Executives, the American Association of Artificial Intelligence, the American College of Managed Care Medicine, the Association of Clinical Scientists, the American Society of Contemporary Medicine and Surgery, the American Society of Law, Medicine and Ethics, the Southern Medical Society, the American Federation for Clinical Research, the National Federation of Catholic Physicians and the Society of Cannabis Clinicians.
Notice Regarding Forward-Looking Statements
This announcement includes "forward-looking statements" involving the Company, the other entities referenced in this announcement, and the respective subsidiaries, affiliates and associates of the Company and such other entities (collective, the "Involved Entities"), which include all statements other than statements of historical facts, including, without limitation, those regarding the financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Involved Entities that could cause the actual results, performance or achievements of the Involved Entities to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the present and future business strategies of the Involved Entities and the environment in which the Involved Entities will operate in the future. These forward-looking statements speak only as of the date of this announcement. The Company, on behalf of itself and each of the Involved Entities, expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in expectations of any Involved Entities with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.
The directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information on AfriAg Global please visit the www.afriagglobal.com or please contact;
AfriAg Global Plc:
David Lenigas (Executive Chairman) +44 (0)20 7440 0640
Peterhouse Capital Limited +44 (0)20 7469 0930
Guy Miller/Fungai Ndoro
